Jiang et al. [43] suggested that topical treatment of specific NF-κB inhibitor (dehydroxymethylepoxyquinomicin) improves 2,4-dinitrochlorobenzene and oxazolone-induced AD-like skin lesions. This evidence concerns the gene NFKB1 and Alzheimer disease.